ClinicalTrials HQ

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Active, not recruiting · NCT05508906 · Registry updated 2026-09-15
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerNeoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorderActive, not recruitingPhase 12026-09-15NCT05508906

3 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Novartis114
Olema Pharmaceuticals, Inc.5
Pfizer431

16 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Advent Health Hematology and OncologyOrlandoUnited States1
Atrium Health Levine Cancer InstituteCharlotteUnited States14
Banner Md Anderson Cancer CenterGilbertUnited States121
Breast Cancer Research Center- Western AustraliaNedlandsAustralia1
Dana Farber Cancer InstituteBostonUnited States300
Henry Ford HealthDetroitUnited States1
Ichan School of Medicine at Mount SinaiNew YorkUnited States14
Macquarie HealthSydneyAustralia1
MD Anderson Cancer CenterHoustonUnited States589
Northwest Medical SpecialtiesTacomaUnited States32
Regents of the University of MinnesotaMinneapolisUnited States4
University of California San Francisco HealthSan FranciscoUnited States1
University of Colorado Cancer CenterAuroraUnited States63
University of IowaIowa CityUnited States284
Vanderbilt-Ingram Cancer CenterNashvilleUnited States48
Washington University, School of MedicineSt LouisUnited States5